Equibles does not estimate personal net worth.
Get an email with a short summary when Teva Pharmaceutical Industries Ltd publishes a filing, an earnings call transcript or a press release.
Get TEVA alertsEli Kalif is recorded as CFO at Teva Pharmaceutical Industries Ltd (TEVA). The newest filing on record that lists Eli Kalif as CFO at Teva Pharmaceutical Industries Ltd (TEVA) is dated March 31, 2026. The proxy statement of Teva Pharmaceutical Industries Ltd reports total compensation of $6,961,991 for Eli Kalif in fiscal 2025, including a base salary of $1,012,687. Disclosed compensation is on record for 7 fiscal years. Eli Kalif has spoken on 5 earnings calls across 1 company, most recently for Teva Pharmaceutical Industries Ltd on May 7, 2025. Teva Pharmaceutical Industries Ltd is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Teva Pharmaceutical Industries Ltd includes Richard Francis (CEO and Board Member), Amir Weiss (Chief Accounting Officer), Andrew Weil (Chief Accounting Officer) and 5 others.
“I really would like to start with the following key messages that I believe are important and I would like you to take away from our call today. Firstly, Q1 came with a solid performance, demonstrating our constant execution.”
“And good morning and good afternoon to everyone. I will begin my review of our 2024 financial results, focusing on our fourth quarter performance.”
“I'll begin my review of our Q3 2024 financial results. Revenues in the third quarter of 2024 were $4.3 billion, an increase of 13% in US dollars, or 15% in local currency terms, compared to the third quarter of 2023.”
“I will begin my review of our Q2 2024 financial results with Slide 26, starting with our GAAP performance. Revenues in the second quarter of 2024 were $4.2 billion, an increase of 7% in US dollars, or 11% in local currency terms, compared to the second quarter of 2023.”
“I’ll begin a review of our 2023 financial results with a main focus being on fourth quarter performance. This will be followed by our non-GAAP outlook for 2024 and some of the important assumptions behind it.”
Start not stated–present
Last confirmed March 31, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, Chief Financial Officer | $1,012,687 | $6,961,991 |
| 2024 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, Chief Financial Officer | $856,486 | $6,175,059 |
| 2023 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, Chief Financial Officer | $781,918 | $4,943,832 |
| 2022 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, Chief Financial Officer | $780,603 | $4,014,617 |
| 2021 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, Chief Financial Officer | $747,175 | $3,544,983 |
| 2020 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, Chief Financial Officer | $681,281 | $3,723,815 |
| 2019 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, Chief Financial Officer | $18,130 | $20,555 |
